|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 811 |
Guru Rank Value : 0.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
159,588 |
275,693 |
319,053 |
656,089 |
Total Sell Value |
$13,270,852 |
$23,760,160 |
$27,661,182 |
$61,420,002 |
Total People Sold |
5 |
6 |
7 |
7 |
Total Sell Transactions |
10 |
21 |
27 |
56 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bienaime Jean Jacques |
Chief Executive Officer |
|
2009-03-05 |
4 |
A |
$10.04 |
$10,039 |
D/D |
1,000 |
11,917 |
|
- |
|
Klein Joseph III |
Director |
|
2009-03-05 |
4 |
B |
$10.07 |
$50,363 |
D/D |
5,000 |
42,500 |
2.39 |
- |
|
Bienaime Jean Jacques |
Director |
|
2009-03-05 |
4/A |
B |
$10.04 |
$10,039 |
D/D |
1,000 |
11,917 |
2.39 |
- |
|
Meier Richard A |
Director |
|
2009-03-03 |
4 |
B |
$10.75 |
$10,750 |
D/D |
1,000 |
3,250 |
2.39 |
- |
|
Klein Joseph III |
Director |
|
2009-03-03 |
4 |
B |
$10.56 |
$52,818 |
D/D |
5,000 |
37,500 |
2.39 |
- |
|
Meier Richard A |
Director |
|
2009-03-02 |
4 |
B |
$11.10 |
$11,100 |
D/D |
1,000 |
2,250 |
2.39 |
- |
|
Kakkis Emil D |
Chief Medical Officer |
|
2009-03-02 |
4 |
AS |
$11.70 |
$92,396 |
D/D |
(7,897) |
39,621 |
|
- |
|
Kakkis Emil D |
Chief Medical Officer |
|
2009-03-02 |
4 |
OE |
$6.43 |
$50,778 |
D/D |
7,897 |
47,518 |
|
- |
|
Fuchs Henry J |
Chief Medical Officer |
|
2009-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
Klein Joseph III |
Director |
|
2009-02-24 |
4 |
B |
$12.08 |
$120,784 |
D/D |
10,000 |
32,500 |
2.39 |
- |
|
Kakkis Emil D |
Chief Medical Officer |
|
2009-02-03 |
4 |
AS |
$19.14 |
$325,373 |
D/D |
(17,000) |
39,621 |
|
- |
|
Kakkis Emil D |
Chief Medical Officer |
|
2009-02-03 |
4 |
OE |
$6.43 |
$109,310 |
D/D |
17,000 |
56,621 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2009-01-22 |
4 |
AS |
$19.05 |
$19 |
D/D |
(1) |
650 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2009-01-22 |
4 |
OE |
$6.13 |
$6 |
D/D |
1 |
651 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2009-01-21 |
4 |
AS |
$19.30 |
$3,415 |
D/D |
(177) |
650 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2009-01-21 |
4 |
OE |
$6.13 |
$1,085 |
D/D |
177 |
827 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2009-01-16 |
4 |
AS |
$21.00 |
$52,521 |
D/D |
(2,501) |
650 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2009-01-16 |
4 |
OE |
$11.74 |
$31,482 |
D/D |
2,501 |
3,151 |
|
- |
|
Kakkis Emil D |
Chief Medical officer |
|
2009-01-02 |
4 |
AS |
$17.57 |
$298,690 |
D/D |
(17,000) |
39,621 |
|
- |
|
Kakkis Emil D |
Chief Medical officer |
|
2009-01-02 |
4 |
OE |
$6.13 |
$107,335 |
D/D |
17,000 |
56,621 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2008-12-22 |
4 |
AS |
$17.18 |
$3,041 |
D/D |
(177) |
650 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2008-12-22 |
4 |
OE |
$6.13 |
$1,085 |
D/D |
177 |
827 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2008-12-08 |
4 |
S |
$17.00 |
$67,988 |
D/D |
(4,000) |
10,917 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2008-12-08 |
4 |
B |
$17.20 |
$68,792 |
D/D |
4,000 |
14,917 |
2.81 |
- |
|
Davis George Eric |
VP, General Counsel |
|
2008-12-04 |
4 |
S |
$16.30 |
$114,079 |
D/D |
(7,000) |
8,180 |
|
- |
|
1312 Records found
|
|
Page 39 of 53 |
|
|